Sunday, January 26, 2014

Kenneth Frazier: Merck CEO

Kenneth Frazier earned his bachelor’s degree from The Pennsylvania State University and obtained a J.D. from Harvard Law School. Kenneth practiced law and was a partner with the Philadelphia law firm Drinker Biddle & Reath. While still in the field of law he made a change in his career joining Merck in 1992 as vice president, general counsel and secretary of the Astra Merck Group.

Since joining Merck Kenneth’s only direction has been up. He was appointed vice president of Public Affairs in 1994, and in 1997, assumed the additional responsibilities of assistant general counsel, corporate staff.  In January 1999 he went up the ladder as vice president and deputy general counsel. By the end of the year he was promoted senior vice president and general counsel. He oversaw the legal and public affairs functions of Merck and The Merck Company Foundation.

Kenneth was promoted to executive vice president and general counsel in November 2006. From 2007 to May 2010 he service as executive vice president and president, Global Human Health. Kenneth then served as president of Merck overseeing the company’s three major division: Global Human Health, Merck’s sales and marketing division for pharmaceutical and vaccine products; Merck Manufacturing Division, Merck’s manufacturing and supply; and Merck Research Laboratories, Merck’s research organization. With his performance he became CEO and member of the board of directors in January 1, 2011 and was elected chairman of the board on December 1, 2011.

Some may have expected a trained business executive or someone with a pharmaceutical background to be heading Merck. Yet when we deal with healthcare we also have to deal with a host of rules and regulations governing the industry. So having someone with a law background has its own advantages.

Merck is a leading global healthcare company and one of the largest in the world. Its scientists have helped to find new ways to treat and prevent illnesses such as the discovery of vitamin B1 and the first measles vaccine. 

No comments:

Post a Comment